Aminosalicylic Acid and Rifampin Intravenous
Determining the interaction of Aminosalicylic Acid and Rifampin Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Aminosalicylic acid may decrease the blood levels and effects of rifAMPin. Your doctor may be able to prescribe alternatives that do not interact or you may need a dose adjustment to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with aminosalicylic acid may decrease the serum levels and therapeutic effects of rifampin. The proposed mechanism involves adsorption of rifampin onto an excipient, bentonite, which can be found in some aminosalicylic acid granules. In one study, rifampin serum levels were reduced by more than 50% when coadministered with aminosalicylic acid granules containing bentonite. In other studies, rifampin levels were not affected when administered with aminosalicylic acid tablets that did not contain bentonite as an excipient.
MANAGEMENT: To avoid this interaction, authorities recommend separating the doses by at least 4 hours (AU) or separating doses by not less than 8 hours (UK) or by using an aminosalicylic acid preparation that does not contain bentonite (US; e.g., Paser(R)).
- Boman G "Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid." Eur J Clin Pharmacol 7 (1974): 217-25
- Boman G, Hanngren A, Malmborg AS, Borga O, Sjoqvist F "Drug interaction: decreased serum concentrations of rifampicin when given with P.A.S." Lancet 1 (1971): 800
- Cerner Multum, Inc. "Australian Product Information." O 0
- Boman G, Borga O, Hanngren A, Malmborg AS, Sjoqvist F "Pharmacokinetic interactions between the tuberculostatics rifampicin, para-aminosalicylic acid and isoniazid." Acta Pharmacol Toxicol (Copenh) 28 (1970): 15
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Boman G, Lundgren P, Stjernstrom G "Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin: adsorption of rifampicin by an excipient, bentonite." Eur J Clin Pharmacol 8 (1975): 293-9
- "Product Information. Paser Granules (aminosalicylic acid)." Jacobus Pharmaceutical Company, Princeton, NJ.
Generic Name: aminosalicylic acid
Brand name: Paser
Synonyms: n.a.
Generic Name: rifampin
Brand name: Rifadin, Rifadin IV, Rimactane
Synonyms: Rifampin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Aminosalicylic Acid-Rifampin Oral, Intravenous
- Aminosalicylic Acid-Rifampin, Isoniazid, and Pyrazinamide
- Aminosalicylic Acid-Rifamycin
- Aminosalicylic Acid-Rifamycin Sodium
- Aminosalicylic Acid-Rifapentine
- Aminosalicylic Acid-Rifater
- Rifampin Intravenous-Aminosyn
- Rifampin Intravenous-Aminosyn 10%
- Rifampin Intravenous-Aminosyn II
- Rifampin Intravenous-Aminosyn II and Dextrose
- Rifampin Intravenous-Aminosyn II Injection
- Rifampin Intravenous-Aminosyn II Sulfite Free